GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ADCT · Dec 31, 2025

ADC Therapeutics SA. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-26-016491General Corporate

Capex intensity38thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.32% · OPTIONAL · VALID

Operating cash generation63thOwn-history percentile · N=8

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-173.52% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

14.85% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure0thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

5.14% · OPTIONAL · VALID

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

92.87% · CORE · NOT_ENOUGH_HISTORY

Operating margin100thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.operating_margin

-149.34% · CORE · VALID

R&D intensity0thOwn-history percentile · N=8

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

127.84% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

8.49% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History8 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20256/8 normalizedLevel 3 Mar 31, 20266/7 normalizedLevel 3 Jun 30, 20266/7 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.00%
Current: 0.32%
Delta: 0.32%

Cash Generation Increased

Previous: -188.13%
Current: -173.52%
Delta: 14.60%

Growth Increased

Previous: -12.58%
Current: 14.85%
Delta: 27.43%

Inventory Pressure Decreased

Previous: 114.55%
Current: 5.14%
Delta: -109.41%

Profitability Increased

Previous: -196.63%
Current: -149.34%
Delta: 47.29%

R And D Intensity Decreased

Previous: 170.18%
Current: 127.84%
Delta: -42.34%

Sbc Intensity Decreased

Previous: 12.70%
Current: 8.49%
Delta: -4.21%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ADCT Fundamental State →Has State · ADC Therapeutics SA →Transitioned To · ADCT GROWTH_INCREASED →Transitioned To · ADCT INVENTORY_PRESSURE_DECREASED →Transitioned To · ADCT PROFITABILITY_INCREASED →Transitioned To · ADCT Fundamental State →Transitioned To · ADCT CAPEX_INTENSITY_INCREASED →Transitioned To · ADCT CASH_GENERATION_INCREASED →Transitioned To · ADCT R_AND_D_INTENSITY_DECREASED →Transitioned To · ADCT SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.